The future of cosmeceuticals

Abstract

The present state of skincare addresses the consequences of photodamage, hormonal influences, and the cumulative impact of exposome exposure throughout a person's life. Treatments within the aesthetic domain either harness biological pathways to achieve rejuvenation, such as retinoids and antioxidants, or suppress them, like lightening ingredients. Emerging advancements encompass techniques that stimulate the differentiation of stem cells to generate younger keratinocytes and fibroblasts, activate macrophages to diminish proinflammatory cellular waste, and restore glycosaminoglycans within the dermal matrix. While these innovations have significantly enhanced the potential of skincare to revitalize the skin in recent years, obstacles to their adoption remain substantial, including complex multistep regimens, the elevated cost of novel technologies, and limited accessibility for a majority of consumers. The next phase of skincare innovation targets the root cause of aging, at the genetic and epigenetic level. By reversing the effect of the exposome at this level, it is conceivable that biological age and chronological age might no longer correlate. Additionally, the integration of artificial intelligence, the identification of biomarkers, and improved accessibility to genetic predisposition lab testing will combine to allow for greater personalization of skincare recommendations.